Neoadjuvant camrelizumab plus chemotherapy versus chemotherapy alone for resectable esophageal squamous cell carcinoma: A Prospective Multicenter randomised controlled study
This prospective multicenter randomized controlled trial demonstrates that neoadjuvant camrelizumab combined with chemotherapy significantly improves pathological response rates and event-free survival compared to chemotherapy alone in patients with resectable esophageal squamous cell carcinoma, while maintaining a favorable safety profile.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, a significant number of people around the world face a diagnosis of esophageal cancer, a disease that affects the tube connecting the throat to the stomach. In many parts of Asia, a specific type of this cancer, known as squamous cell carcinoma, is particularly common. For patients whose cancer has spread to nearby tissues or lymph nodes but has not yet traveled to distant organs, the standard approach has long been a combination of chemotherapy and surgery. Doctors give chemotherapy first to try to shrink the tumor, followed by an operation to remove it. However, this traditional method often leaves behind microscopic traces of cancer, and the chance of the disease returning remains high. In recent years, a new class of drugs called immune checkpoint inhibitors has changed how doctors fight many cancers. These medicines do not attack the cancer directly; instead, they remove the "brakes" that cancer cells use to hide from the body's own immune system, allowing the immune cells to recognize and destroy the tumor. While these drugs have shown great promise in treating advanced cancer, it was unclear whether adding them to the pre-surgery phase would help patients with cancer that could still be removed.
A team of researchers from hospitals in Anhui Province, China, set out to answer this question with a large, carefully planned study. They focused on patients with locally advanced esophageal squamous cell carcinoma who were healthy enough to undergo surgery. The team recruited 248 adults and randomly assigned them to one of two groups. One group received the standard treatment: a combination of chemotherapy drugs. The other group received the same chemotherapy, but with the addition of an immune therapy drug called camrelizumab. Both groups received their treatments for several weeks before undergoing surgery to remove the cancer. The researchers then examined the removed tissue under a microscope to see how much of the cancer had been killed by the treatment, and they followed the patients for several years to see how long they remained free of the disease.
The results of the study showed that adding the immune therapy to the chemotherapy made a clear difference in how well the treatment worked before surgery. When the surgeons removed the tumors, they found that the group receiving the combination therapy had a much higher rate of complete tumor disappearance. In the group that received only chemotherapy, about 11.5 percent of patients had no cancer cells left in their surgical specimens. In the group that received the immune therapy plus chemotherapy, this number rose to 20.7 percent. Furthermore, a larger portion of the combination group showed a major response, meaning that very few cancer cells remained, compared to the group that received only chemotherapy. The researchers also looked at how long patients stayed free from the cancer returning or spreading. After three years, 75.4 percent of the patients in the combination group were still free of these events, compared to 62.2 percent in the chemotherapy-only group. This suggests that the immune therapy helped keep the cancer at bay for a longer period.
Safety was a major concern for the researchers, as adding a new drug to a rigorous treatment plan could potentially cause more side effects or make the surgery more difficult. The study found that the combination treatment was safe and did not increase the risks associated with the operation. The rate of serious complications after surgery was similar in both groups, and the surgeons were able to remove the cancer completely in nearly all cases in both groups. The immune therapy did not make the surgery harder or more dangerous. While the study did not yet show a statistically significant difference in the total length of life between the two groups, the researchers noted that the survival curves began to separate after about three years, hinting that the long-term benefits might become clearer with more time.
This study provides promising evidence that combining immune therapy with standard chemotherapy before surgery offers better outcomes for patients with resectable esophageal squamous cell carcinoma than chemotherapy alone, particularly regarding tumor shrinkage and disease-free survival. It demonstrates that this approach can significantly shrink or eliminate tumors before the operation and improve the time patients live without their cancer returning, all without adding extra danger to the surgical process. However, because the data on overall survival is still maturing and not yet statistically significant, the researchers emphasize that further long-term follow-up is needed to confirm the full impact on life expectancy. The findings suggest this combination is a highly effective treatment option that warrants further investigation to potentially establish it as a new standard of care for this challenging disease. The work highlights how modern medicine is evolving, using the body's own defenses to fight cancer more effectively than traditional methods alone.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.